The GW VRU Director, Dr. David Diemert, co-authored an article assessing the value of public health, economic, and societal value of developing a vaccine to prevent and reduce the transmission of Schistosomiasis. Endemic in 78 countries, it is estimated that approximately 236 million people were treated for Schistosomiasis in 2019. This article evaluates the global public health need for a vaccine.
Vaccine Value Profile for Schistosomiasis
Latest News
Uganda has detected what appears to be a localized outbreak of Marburg virus disease, with two cases identified in a single family, according to a source familiar with the situation, although the Ugandan government had not yet publicly confirmed the outbreak at the time of publication. The…
The GW VRU is a site for a clinical trial to examine Pfizer's new C. diff vaccine.
This was a phase 2, randomized, open-label, non-placebo controlled trial to evaluate two partial doses o the Modified Vaccinia Ankara-Bavarian Nordin (MVA-BN) vaccine for protection against mpox.